We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chronic Lack of Quality Testing Leads to FDA Alert for Compounder

Chronic Lack of Quality Testing Leads to FDA Alert for Compounder

August 1, 2014

The FDA asked healthcare professionals to watch out for drugs compounded by a Dallas-based pharmacy after a recent inspection revealed 22 lots of sterile drugs failed quality tests.

The agency issued a July 19 safety alert on drugs compounded by Downing Labs and its subsidiary Nuvision Pharmacy following a June to July inspection of the compounder’s facility that found the lots failed sterility or endotoxin tests from April 2013 to June 23, 2014. “In each case, the investigations were either absent or incomplete,” says a Form 483 issued July 16.

Downing’s contract laboratory determined that a lot of folic acid 10 mg and two lots of cyanocobalamin 1 mg/ml failed sterility and were contaminated by bacteria. However, no investigation was performed as to how the lot failed sterility, says the 483 with 15 observations.

All of the lots were destroyed except for two, with a lot of cyanocobalamin awaiting distribution after being re-tested for sterility and endotoxins. A lot of folic acid is being held in quarantine pending destruction, the FDA says.

The investigator also found that Downing didn’t do endotoxin testing on approximately 180 lots from April 2013 to June 2014.

Downing’s subsidiary Nuvision has tangled with the FDA before, rejecting a request from the agency last summer to recall questionably sterile products. The pharmacy noted at the time that it follows U.S. Pharmacopeia standards for compounders.

Downing did not return a request for comment as of press time.

Drug GMP training never ends, and rightly so. But there’s no point in reinventing the training wheel — not when a top-quality option is available. Train your staff the easy way with Drug GMP Training Course: A 17-Module Customizable Training Series.

Drugs GMPs

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing